Amicus Therapeutics

@amicusrx1

Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases.

Cranbury, NJ
Vrijeme pridruživanja: listopad 2014.

Tweetovi

Blokirali ste korisnika/cu @amicusrx1

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @amicusrx1

  1. Prikvačeni tweet
    30. sij

    America’s biopharmaceutical industry has lost the trust of many of our patients. We’re committed to reversing this trend by pledging a new Commitment to Patients and the Public:

    Poništi
  2. 31. sij

    Many business practices of the biopharmaceutical industry are simply unacceptable when the public health is at stake. Many practices do not put patients first. This must change - and we must be the agents of that change.

    Poništi
  3. 17. sij

    Amicus is proud to support the 2020 Annual Dinner Meeting & Innovation Celebration. We will be there and hope to see you on February 6. For more information, visit !

    Poništi
  4. 11. stu 2019.

    : A full replay of today’s 3Q19 conference call and webcast can be accessed via the Investor Relations section our website.

    Poništi
  5. 11. stu 2019.

    Tune in now to our 3Q19 conference call and webcast.

    Poništi
  6. 11. stu 2019.

    Join Amicus Therapeutics at 8:30 a.m. ET for our 3Q19 conference call and webcast.

    Poništi
  7. 11. stu 2019.

    This morning, we announced our 3Q19 and corporate updates. Live conference call and webcast this morning at 8:30 a.m. ET

    Poništi
  8. proslijedio/la je Tweet
    28. lis 2019.

    A standing ovation for the inspiration speech from John Crowley, Chairman and CEO, Co-Founder, Amicus Therapeutics, at the 2019 Annual Meeting & Expo, where he was a keynote speaker speaking about when drug research is personal.

    Poništi
  9. 10. lis 2019.

    : A full audio webcast replay of today’s can be accessed via the Investors Relations page of the Amicus corporate website.

    Poništi
  10. 10. lis 2019.

    As comes to a close, we will continue to advance our vision to create significant value for patients and shareholders

    Poništi
  11. 10. lis 2019.

    Dr. James Wilson presents an overview of the Amicus- collaboration and next generation research program to drive the second wave of innovation for

    Poništi
  12. 10. lis 2019.

    Our Chief Science Officer Hung Do describes our natural evolution from pharmacological chaperones to next-generation ERTs to .

    Poništi
  13. 10. lis 2019.

    Our Chief Medical Officer Jay Barth is discussing our latest clinical data for AT-GAA in disease.

    Poništi
  14. 10. lis 2019.

    We have had several opportunities to deliver significant value for shareholders and patients.

    Poništi
  15. 10. lis 2019.

    Our chairman & CEO John F. Crowley kicks off the by sharing a few words on our vision, mission and strategy. Tune in now!

    Poništi
  16. 10. lis 2019.

    Today, the Amicus team will host an Analyst Day in NYC. Tune in to learn more about the Company’s vision and leadership in discovering, developing and delivering medicines for people living with rare diseases. Live webcast today at 8:30 a.m. ET.

    Poništi
  17. 10. lis 2019.

    Amicus announces corporate updates and highlights for

    Poništi
  18. 3. lis 2019.

    Our Chairman and CEO, John F. Crowley, will be discussing the importance of a patient-dedicated company culture during his keynote session at the 17th . Learn more at: .

    Poništi
  19. 2. lis 2019.

    Amicus Chairman & CEO, John F. Crowley presenting at the Cantor Fitzgerald Global Healthcare Conference today in NYC.

    Poništi
  20. 2. lis 2019.

    will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, October 2 at 8:20 a.m. ET

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·